Skip to content
Dosage GuideResearch Reference

Ipamorelin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Ipamorelin. All information is for educational purposes only.

Quick Answer

Ipamorelin is typically researched at 100–300 mcg per injection, administered subcutaneously 2–3 times daily. The most common protocol pairs 100–200 mcg ipamorelin with 100 mcg CJC-1295 per injection for synergistic GH release. Timing on an empty stomach is essential — insulin blunts the pituitary GH response. No human clinical dosing trials have been completed.

→ Ipamorelin Benefits→ Ipamorelin Side Effects→ Full Ipamorelin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 100–300 mcg per injection, 2–3× daily

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

GH Optimization / Anti-Aging (with CJC-1295)

100–200 mcg ipamorelin + 100 mcg CJC-12951–2× daily
Duration

12–16 weeks

Standard combination stack. Pre-bed injection most important — maximizes the natural nocturnal GH pulse. Morning injection optional for anti-aging and body composition goals.

Fat Loss / Body Composition

200–300 mcg ipamorelin + 100 mcg CJC-12952–3× daily
Duration

16–20 weeks

Higher ipamorelin doses and 3× daily injections maximize cumulative GH exposure for lipolytic effect. Fasted state essential at each injection.

Sleep Quality Improvement

100–200 mcg ipamorelin + 100 mcg CJC-12951× daily, 30–60 min before sleep
Duration

8–12 weeks

Pre-sleep dosing is the most evidence-aligned timing. GH elevation during slow-wave sleep enhances sleep depth and restoration. Ipamorelin's clean profile (no cortisol spike) makes it preferable to GHRP-2/GHRP-6 for this application.

Recovery / Injury Healing

200 mcg ipamorelin + 100 mcg CJC-12952× daily
Duration

8–12 weeks

GH and IGF-1 elevation accelerates tissue repair. Can be combined with BPC-157 or TB-500 for connective tissue injuries (different mechanism, complementary effects).

Timing & Frequency

Ipamorelin has a short half-life (~2 hours), requiring multiple daily injections for sustained GH elevation. Critical timing rule: inject in a fasted state (2+ hours after last meal, no food for 30–60 minutes post-injection). Elevated insulin suppresses GH release at the pituitary level, significantly blunting the ipamorelin response. Pre-bed timing is the single most impactful injection window.

Cycle Guidance

Standard research cycles: 12–20 weeks on, 8–12 weeks off. Ipamorelin does not significantly suppress natural GH axis function (unlike synthetic HGH), so recovery from cycling is typically smooth. Extended cycles (20+ weeks) are used by some researchers given the favorable tolerability, but long-term data is absent. Blood IGF-1 levels are a useful monitoring biomarker during cycles.

Reconstitution Reference

Quick reference for reconstituting Ipamorelin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 2 mg or 5 mg per vial
BAC Water Volume2 mL per 2 mg vial = 1 mg/mL (1,000 mcg/mL)
Concentration & DrawAt 1 mg/mL: 200 mcg dose = 0.2 mL = 20 units on a 100-unit insulin syringe
StorageRefrigerate at 2–8°C after reconstitution. Use within 30 days.
StabilityReconstituted: 30 days refrigerated. Lyophilized: 12–24 months.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard ipamorelin dosage?
100–300 mcg per injection is the standard research range. Most protocols use 100–200 mcg per injection, 2–3 times daily, paired with CJC-1295. Higher doses (300 mcg) are used for more aggressive body composition or recovery protocols. Unlike some GHRPs, ipamorelin has a relatively flat dose-response above 100–200 mcg for GH release.
How many times per day should I inject ipamorelin?
Given ipamorelin's ~2 hour half-life, 2–3 daily injections are needed for sustained GH optimization. A practical approach for most: pre-bed injection (most important, aligns with natural GH pulse) + optional morning fasted injection. Three-times-daily protocols (morning, pre-workout, pre-bed) are used for more aggressive body composition goals.
Can ipamorelin be used without CJC-1295?
Yes. Ipamorelin alone stimulates GH release via the ghrelin receptor. However, the synergistic combination with CJC-1295 (which works via the separate GHRH receptor) produces substantially greater GH release — often 2–4× more than ipamorelin alone. Ipamorelin-only protocols are used by those who prefer simpler protocols or want to minimize injected substances.
How do I calculate ipamorelin injection volume?
Example: Reconstitute 2 mg ipamorelin in 2 mL BAC water = 1,000 mcg/mL. For 200 mcg: 200 ÷ 1,000 = 0.2 mL = 20 units on a 100-unit syringe. Use the Reconstitution Calculator (/tools/reconstitution-calculator) for other concentrations. Many researchers pre-mix ipamorelin and CJC-1295 in the same syringe for each injection.
Can I mix ipamorelin and CJC-1295 in the same syringe?
Yes — this is common practice. After reconstituting each peptide separately, draw the desired volume of each into the same insulin syringe for a single injection. This convenience approach has no documented stability or compatibility issues within the timeframe of immediate administration. Do not pre-mix and store the combination.
How long before results from ipamorelin?
Acute GH elevation occurs within 15–30 minutes of each injection. Subjective improvements in sleep quality are often reported within 2–4 weeks. Body composition changes (fat loss, lean mass improvements) typically require 8–12 weeks of consistent dosing with appropriate training and nutrition. IGF-1 blood levels — a measurable proxy for GH activity — typically rise within 2–4 weeks.

References

  1. 1
    Ipamorelin, the first selective growth hormone secretagogue(1999)PubMed ↗
  2. 2
    Growth hormone secretagogues: spectrum of physiological activities(1998)PubMed ↗
  3. 3
    Ipamorelin — a new growth hormone releasing peptide(1998)PubMed ↗
  4. 4
    The selective GH secretagogue ipamorelin activates the hypothalamic GH axis(2000)PubMed ↗
  5. 5
    GH secretagogues and the regulation of GH secretion(1999)PubMed ↗

Last updated: 2026-02-26